Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto, Dirk Schadendorf, Carola Berking, et al.
The Lancet Oncology (2013) Vol. 14, Iss. 3, pp. 249-256
Closed Access | Times Cited: 620

Showing 1-25 of 620 citing articles:

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow, Jason Chesney, Anna C. Pavlick, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 21, pp. 2006-2017
Open Access | Times Cited: 2639
Comprehensive Characterization of Cancer Driver Genes and Mutations
Matthew H. Bailey, Collin Tokheim, Eduard Porta‐Pardo, et al.
Cell (2018) Vol. 173, Iss. 2, pp. 371-385.e18
Open Access | Times Cited: 2025
Melanoma
Dirk Schadendorf, Alexander C.J. van Akkooi, Carola Berking, et al.
The Lancet (2018) Vol. 392, Iss. 10151, pp. 971-984
Closed Access | Times Cited: 1228
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke, Keith T. Flaherty, Antoni Ribas, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 8, pp. 463-482
Closed Access | Times Cited: 1087
Targeting RAS–ERK signalling in cancer: promises and challenges
Ahmed A. Samatar, Poulikos I. Poulikakos
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 12, pp. 928-942
Closed Access | Times Cited: 1006
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 5, pp. 603-615
Open Access | Times Cited: 899
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore, Scott Rosenberg, Frank McCormick, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 8, pp. 533-552
Open Access | Times Cited: 810
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Matthew Holderfield, Marian M. Deuker, Frank McCormick, et al.
Nature reviews. Cancer (2014) Vol. 14, Iss. 7, pp. 455-467
Open Access | Times Cited: 767
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Reinhard Dummer, Axel Hauschild, Merlin Guggenheim, et al.
Annals of Oncology (2012) Vol. 23, pp. vii86-vii91
Open Access | Times Cited: 685
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
Jack F. Shern, Li Chen, Juliann Chmielecki, et al.
Cancer Discovery (2014) Vol. 4, Iss. 2, pp. 216-231
Open Access | Times Cited: 677
Melanoma treatment in review
Beatriz Domingues, José Manuel Lopes, Paula Soares, et al.
ImmunoTargets and Therapy (2018) Vol. Volume 7, pp. 35-49
Open Access | Times Cited: 601
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
David Clark, Saravana M. Dhanasekaran, Francesca Petralia, et al.
Cell (2019) Vol. 179, Iss. 4, pp. 964-983.e31
Open Access | Times Cited: 566
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Christopher J. Caunt, Matthew J. Sale, Paul D. Smith, et al.
Nature reviews. Cancer (2015) Vol. 15, Iss. 10, pp. 577-592
Closed Access | Times Cited: 554
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 4, pp. 435-445
Closed Access | Times Cited: 433
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
Richard D. Carvajal, Jeffrey A. Sosman, J. Fernando Quevedo, et al.
JAMA (2014) Vol. 311, Iss. 23, pp. 2397-2397
Open Access | Times Cited: 397
The clinical development of MEK inhibitors
Yujie Zhao, Alex A. Adjei
Nature Reviews Clinical Oncology (2014) Vol. 11, Iss. 7, pp. 385-400
Closed Access | Times Cited: 377
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Reinhard Dummer, Axel Hauschild, Nicole Lindenblatt, et al.
Annals of Oncology (2015) Vol. 26, pp. v126-v132
Open Access | Times Cited: 376
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bédard, Josep Tabernero, Filip Janků, et al.
Clinical Cancer Research (2014) Vol. 21, Iss. 4, pp. 730-738
Open Access | Times Cited: 298
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan, Christine A. Pratilas, Alexis M. Jones, et al.
Cancer Research (2014) Vol. 74, Iss. 8, pp. 2340-2350
Open Access | Times Cited: 285
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Murugan Kalimutho, Kate Parsons, Deepak Mittal, et al.
Trends in Pharmacological Sciences (2015) Vol. 36, Iss. 12, pp. 822-846
Closed Access | Times Cited: 274
MEK and the inhibitors: from bench to bedside
Akintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, et al.
Journal of Hematology & Oncology (2013) Vol. 6, Iss. 1
Open Access | Times Cited: 270
MEK in cancer and cancer therapy
Cindy Neuzillet, Annemilaï Tijeras‐Raballand, Louis de Mestier, et al.
Pharmacology & Therapeutics (2013) Vol. 141, Iss. 2, pp. 160-171
Closed Access | Times Cited: 245
Current Development Status of MEK Inhibitors
Ying Cheng, Hongqi Tian
Molecules (2017) Vol. 22, Iss. 10, pp. 1551-1551
Open Access | Times Cited: 241
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Ester Simeone, Giusy Gentilcore, Diana Giannarelli, et al.
Cancer Immunology Immunotherapy (2014) Vol. 63, Iss. 7, pp. 675-683
Open Access | Times Cited: 240
Epidemiology of brain metastases and leptomeningeal disease
Nayan Lamba, Patrick Y. Wen, Ayal A. Aizer
Neuro-Oncology (2021) Vol. 23, Iss. 9, pp. 1447-1456
Open Access | Times Cited: 236
Page 1 - Next Page

Scroll to top